ATE31718T1 - Mevalolacton-analoga und derivate, verfahren zur herstellung, pharmazeutische zusammenstellungen die sie enthalten und ihre verwendung als arzneimittel. - Google Patents

Mevalolacton-analoga und derivate, verfahren zur herstellung, pharmazeutische zusammenstellungen die sie enthalten und ihre verwendung als arzneimittel.

Info

Publication number
ATE31718T1
ATE31718T1 AT83810548T AT83810548T ATE31718T1 AT E31718 T1 ATE31718 T1 AT E31718T1 AT 83810548 T AT83810548 T AT 83810548T AT 83810548 T AT83810548 T AT 83810548T AT E31718 T1 ATE31718 T1 AT E31718T1
Authority
AT
Austria
Prior art keywords
hydrogen
benzyloxy
phenoxy
trifluoromethyl
fluoro
Prior art date
Application number
AT83810548T
Other languages
German (de)
English (en)
Inventor
Faizulla Gulamhusein Kathawala
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Application granted granted Critical
Publication of ATE31718T1 publication Critical patent/ATE31718T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT83810548T 1982-11-22 1983-11-22 Mevalolacton-analoga und derivate, verfahren zur herstellung, pharmazeutische zusammenstellungen die sie enthalten und ihre verwendung als arzneimittel. ATE31718T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44366882A 1982-11-22 1982-11-22
US54885083A 1983-11-04 1983-11-04
EP83810548A EP0114027B1 (en) 1982-11-22 1983-11-22 Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
ATE31718T1 true ATE31718T1 (de) 1988-01-15

Family

ID=27033614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83810548T ATE31718T1 (de) 1982-11-22 1983-11-22 Mevalolacton-analoga und derivate, verfahren zur herstellung, pharmazeutische zusammenstellungen die sie enthalten und ihre verwendung als arzneimittel.

Country Status (18)

Country Link
EP (1) EP0114027B1 (enExample)
JP (1) JPH0347167A (enExample)
AT (1) ATE31718T1 (enExample)
AU (1) AU570021B2 (enExample)
CA (1) CA1210405A (enExample)
CY (1) CY1579A (enExample)
DE (2) DE3375137D1 (enExample)
DK (2) DK359284D0 (enExample)
FI (1) FI77228C (enExample)
GR (1) GR79042B (enExample)
HK (1) HK11191A (enExample)
HU (1) HU204253B (enExample)
IE (1) IE56262B1 (enExample)
IL (1) IL70286A (enExample)
LU (1) LU88670I2 (enExample)
NL (1) NL950022I2 (enExample)
NZ (1) NZ206338A (enExample)
WO (1) WO1984002131A1 (enExample)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US5001255A (en) * 1984-12-04 1991-03-19 Sandoz Pharm. Corp. Idene analogs of mevalonolactone and derivatives thereof
ATE60571T1 (de) * 1984-12-04 1991-02-15 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
US4851427A (en) * 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
AU598775B2 (en) * 1985-10-25 1990-07-05 Sandoz Ag Heterocyclic analogs of mevalonolactone
IL83821A0 (en) * 1986-09-10 1988-02-29 Sandoz Ag Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
US4735958A (en) * 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US4898949A (en) * 1987-02-25 1990-02-06 Bristol-Myers Company Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US4897490A (en) * 1987-02-25 1990-01-30 Bristol-Meyers Company Antihypercholesterolemic tetrazole compounds
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
US4904646A (en) * 1987-05-22 1990-02-27 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-COA reductase inhibitors
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US5185328A (en) * 1987-08-20 1993-02-09 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
DE3739882A1 (de) * 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
AU2888289A (en) * 1988-01-27 1989-07-27 May & Baker Limited Isoquinolinones
NO890522L (no) * 1988-02-25 1989-08-28 Bayer Ag Substituerte imidazolinoner og imidazolinthioner.
US5024999A (en) * 1988-04-26 1991-06-18 Nissan Chemical Industries Ltd. Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
JP2890448B2 (ja) * 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5010205A (en) * 1988-08-23 1991-04-23 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl intermediates
US4870187A (en) * 1988-08-23 1989-09-26 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl compounds
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
MY105067A (en) * 1988-10-13 1994-07-30 Novartis Ag Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof.
JPH04270285A (ja) * 1988-11-14 1992-09-25 Nissan Chem Ind Ltd ピラゾロピリミジン系メバロノラクトン類
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB8919091D0 (en) * 1989-08-22 1989-10-04 Fujisawa Pharmaceutical Co Pyrroloquinoline compounds
IT1237792B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
DE4243279A1 (de) * 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
JP2736599B2 (ja) * 1993-07-23 1998-04-02 株式会社キッツ ボールバルブのシート構造
DE19513716A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Substituierte 2-Phenylindol-Derivate
US6425881B1 (en) 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
WO1997049681A1 (en) * 1996-06-24 1997-12-31 Astra Aktiebolag (Publ) Polymorphic compounds
EP0988289A2 (en) 1997-06-05 2000-03-29 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2001092223A1 (en) 2000-05-26 2001-12-06 Ciba Specialty Chemicals Holding Inc. Process for the preparation of indole derivatives and intermediates of the process
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
CN1509180A (zh) 2001-04-18 2004-06-30 ԭ���ø� 用脂肪族聚胺治疗综合症x的方法
DE60226044T2 (de) * 2001-08-03 2009-05-14 Ciba Holding Inc. Kristalline formen von fluvastatin-natrium
US6696473B2 (en) 2001-12-21 2004-02-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
AU2003230835A1 (en) 2002-04-12 2003-10-27 Merck & Co., Inc. Tyrosine kinase inhibitors
JP4553899B2 (ja) 2003-08-21 2010-09-29 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
CN100404479C (zh) * 2003-08-27 2008-07-23 住友化学株式会社 芳族不饱和化合物的制备方法
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
KR20070085874A (ko) * 2004-12-09 2007-08-27 머크 앤드 캄파니 인코포레이티드 에스트로겐 수용체 조절제
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
US8722734B2 (en) 2005-03-02 2014-05-13 Merck Sharp & Dohme Corp. Composition for inhibition of cathepsin K
WO2007002563A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
EP1912953B1 (en) * 2005-07-28 2016-08-17 LEK Pharmaceuticals d.d. Process for the synthesis of rosuvastatin calcium
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
WO2007059372A2 (en) 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
ATE431818T1 (de) 2006-04-20 2009-06-15 Italiana Sint Spa Verfahren zur herstellung von fluvastatin-natrium
ES2378281T3 (es) 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
BRPI0812159A2 (pt) 2007-05-21 2017-05-02 Novartis Ag inibidores de csf-1r, composições e métodos de uso
ES2330184B1 (es) 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
HRP20170194T1 (hr) 2009-05-28 2017-05-19 Exelixis Patent Company Llc Lxr modulatori
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
BR112012023021A2 (pt) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
JPWO2012046772A1 (ja) 2010-10-06 2014-02-24 国立大学法人 東京大学 リンパ浮腫予防治療剤
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP2797641B1 (en) 2011-12-29 2019-07-10 Trustees Of Tufts College Functionalization of biomaterials to control regeneration and inflammation responses
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
EP2968275B1 (en) 2013-03-15 2017-11-29 Bristol-Myers Squibb Company Lxr modulators
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
CA2923272A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
WO2020140098A1 (en) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof

Also Published As

Publication number Publication date
NL950022I2 (nl) 1996-12-02
GR79042B (enExample) 1984-10-02
FI77228C (fi) 1989-02-10
IE832713L (en) 1984-05-22
FI842615A7 (fi) 1984-06-28
IL70286A0 (en) 1984-02-29
EP0114027B1 (en) 1988-01-07
DK165244C (da) 1993-03-22
CA1210405A (en) 1986-08-26
DE3375137D1 (en) 1988-02-11
NL950022I1 (enExample) 1996-01-02
DK97890D0 (da) 1990-04-19
HUT35642A (en) 1985-07-29
DE19475017I2 (de) 2003-02-20
AU570021B2 (en) 1988-03-03
AU2261283A (en) 1984-06-18
CY1579A (en) 1991-12-20
IL70286A (en) 1987-08-31
HK11191A (en) 1991-02-13
EP0114027A1 (en) 1984-07-25
DK359284A (da) 1984-07-20
JPH0440343B2 (enExample) 1992-07-02
LU88670I2 (fr) 1996-04-29
DK359284D0 (da) 1984-07-20
FI77228B (fi) 1988-10-31
JPH0347167A (ja) 1991-02-28
IE56262B1 (en) 1991-06-05
HU204253B (en) 1991-12-30
NZ206338A (en) 1987-08-31
WO1984002131A1 (fr) 1984-06-07
DK97890A (da) 1990-04-19
FI842615A0 (fi) 1984-06-28
DK165244B (da) 1992-10-26

Similar Documents

Publication Publication Date Title
DE19475017I2 (de) Mevalolacton-Analoga und Derivate Verfahren zur Hetstellung pharmazeutische Zusammenstellungen die sie enthalten und ihre Verwendung als Arzneimittel
DE3278501D1 (en) Antiviral compounds
PL262105A1 (en) The method of manufacture of new derivatives of benzimidazole
ATE23326T1 (de) Mevalonslakton-analoge und ihre derivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zusammensetzungen sowie deren verwendung als heilmittel.
IE800671L (en) Pyranones
ATE18549T1 (de) 1-carboxyalkanoylindolin-2-carbonsaeure-ester, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
IL75116A (en) Ethyl substituted-beta-carboxylates,process for the preparation thereof and pharmaceutical compositions containing the same
DE3868013D1 (de) Thiazolderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
ATE15370T1 (de) 3-piperidinyl-indole derivate, ihre salze, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende arzneimittel.
DE3660764D1 (en) Triazole derivatives, process for their preparation and pharmaceutical compositions containing them
DE3782619D1 (de) 1-hydroxyalkylxanthine, verfahren zu ihrer herstellung und sie enthaltende medikamente.
ZA81401B (en) N-alkyl-carbamic acid indan-4-yl esters,processes for their preparation and their use as fungicides
ATE49003T1 (de) Pregnane derivate, verfahren zu ihrer herstellung und pharmazeutische zusammenstellungen, die sie enthalten.